What is the Core Service? The service provider uses an iterative, in vitro selection process called SELEX (Systematic Evolution of Ligands by EXponential Enrichment) to screen vast random oligonucleotide libraries (10^14 - 10^15 unique sequences) against your target protein. The output is a set of characterized aptamer sequences that bind to the viral capsid. Standardized Screening Workflow A professional service will manage this entire pipeline: 1. Project Design & Target Preparation: Target Discussion: Defining the specific capsid protein (e.g., HIV-1 CA, HBV core, SARS-CoV-2 N), its form (full-length, domain, assembled capsid/nucleocapsid), and purity. Target Immobilization: The protein is often immobilized on a solid support (beads, plate) to facilitate separation of bound/unbound sequences. Some services offer solution-phase or capillary electrophoresis (CE-SELEX) methods for higher stringency. 2. SELEX Selection Rounds (Cycles 5-15): Incubation: The oligonucleotide library is incubated with the target. Partitioning: Unbound sequences are washed away; bound sequences are retained. Elution: Bound aptamers are eluted (e.g., by heating, denaturing agents). Amplification: Eluted aptamers are amplified by PCR (for DNA) or RT-PCR (for RNA). Purification: The amplified pool is purified for the next selection round. Counter-Selection: To ensure specificity, the pool is often passed through a negative control (e.g., irrelevant protein, cell lysate) to remove non-specific binders. 3. Sequencing & Identification: High-Throughput…
What is an Aptamer? First, a quick definition: Aptamers are short, single-stranded DNA or RNA oligonucleotides that bind to a specific target molecule (like proteins, toxins, cells) with high affinity and specificity. They are often called "chemical antibodies" but offer advantages like easier synthesis, higher stability, and lower cost. What is Toxin-Targeted Aptamer Screening? This service involves the in vitro selection and development of custom aptamers designed to bind specifically to a toxic substance. The core technology is called SELEX (Systematic Evolution of Ligands by EXponential enrichment). The process screens vast random libraries (10^14 - 10^15 different sequences) against the toxin to isolate the few sequences that bind tightly and specifically. Key Steps in the Service Pipeline Project Consultation & Target Definition: Clarify the toxin (e.g., mycotoxins like Aflatoxin B1, marine toxins like Saxitoxin, bacterial toxins like Botulinum, environmental toxins like heavy metals). Define the desired application (Detection/Biosensing, Neutralization, Capture/Purification). Specify the sample matrix (food extract, blood serum, environmental water). Library Design & SELEX Strategy: Design of a naive single-stranded DNA or RNA library. Choosing the appropriate SELEX variant: Negative Selection/Counter-SELEX: To exclude sequences that bind to similar non-toxin molecules or the assay matrix (crucial for specificity). Capture-SELEX: For small toxins that can't be immobilized. Cell-SELEX: If the…
Core Concept of NGS-SELEX Traditional SELEX uses a few rounds of selection and cloning/Sanger sequencing of a handful of clones. NGS-SELEX performs deep sequencing (millions to billions of reads) at every selection round. This allows you to: Track the entire evolution of the oligonucleotide pool in real-time. Identify enriched sequences and families early. Perform sophisticated bioinformatics analysis to find winners, not just rely on final round abundance. Dramatically reduce the number of selection rounds needed (often 3-6 rounds instead of 8-15). Standard Service Workflow A full-service provider would typically offer the following pipeline: 1. Project Design & Library Synthesis Consultation: Target properties (protein, small molecule, cell), desired aptamer properties (Kd, specificity, buffer conditions). Library Design: Standard (40-60 nt random region) or custom (doped libraries, modified nucleotides like 2'-F, 2'-OMe, SOMAmers). Primer & Library Synthesis: Providing the initial, highly diverse DNA or RNA library (10^14 - 10^15 unique sequences). 2. SELEX Selection Immobilization: Immobilizing the target (on beads, column, plate) or using solution-based techniques (capture-SELEX, toggle-SELEX). Counter-Selection: Including steps to remove binders to immobilization matrix or off-targets. Stringency Control: Increasing selection pressure over rounds (e.g., reduced target concentration, increased wash stringency). Amplification: Careful PCR (with optimization to minimize bias) to regenerate the pool for the next round. 3. NGS & Core Bioinformatics Sample Preparation: Preparing sequencing…
Toggle-SELEX is a sophisticated and powerful variant of the traditional SELEX process for aptamer development, specifically designed to generate aptamers that recognize multiple, closely related targets or a specific epitope common across different species/conditions. Let's break down what an Aptamer Screening Service using Toggle-SELEX entails, its applications, and what you should consider when selecting a service provider. What is Toggle-SELEX? The core idea of Toggle-SELEX is to "toggle" or alternate the selection pressure between two (or more) related target molecules during the SELEX rounds. Traditional SELEX: Uses a single target to evolve aptamers with high affinity for that specific target. It often negatively selects against related molecules (counter-selection) to ensure specificity. Toggle-SELEX: Actively uses two positive selection targets in an alternating pattern. For example: Round 1: Select against Target A (e.g., human protein). Round 2: Select against Target B (e.g., mouse ortholog of the same protein). Round 3: Back to Target A, and so on. Counter-selection against unrelated structures is still used to maintain general specificity. This process enriches for nucleic acid sequences that bind to a conserved structural epitope present on both targets, while sequences that bind to unique epitopes on only one target are filtered out. Key Applications of Toggle-SELEX This method is invaluable when you need cross-reactive or broad-spectrum recognition: Cross-Species Reactive Aptamers: Develop aptamers for preclinical research. For example, an…
What is CE-SELEX? SELEX (Systematic Evolution of Ligands by EXponential Enrichment) is the standard process for aptamer development. It involves iterative rounds of selection and amplification to enrich nucleic acid sequences that bind tightly to a target molecule. Traditional SELEX often uses immobilization of the target on beads or filters, which can be slow (8-15 rounds) and may introduce bias by selecting for sequences that bind to the immobilization matrix itself. CE-SELEX uses Capillary Electrophoresis as the separation mechanism. The key principle is that when an aptamer binds to its target, it forms a complex with a different charge-to-size ratio, causing it to migrate at a different time (shifted peak) in the capillary compared to the unbound nucleic acid library. This complex can be isolated and collected with exquisite precision. Core Advantages of a CE-SELEX Screening Service A service provider offering CE-SELEX delivers significant benefits: Extreme Speed and Efficiency: Often requires only 2-4 rounds of selection to obtain high-affinity aptamers (nanomolar to picomolar Kd), compared to many more rounds in traditional SELEX. This translates to weeks or months of time saved. Solution-Phase Selection: The target is free in solution, eliminating immobilization bias. This allows for selection against targets in their native conformation and enables selection for small molecules and…
Aptamers are single-stranded oligonucleotides that fold into defined architectures and bind to targets such as proteins. In binding proteins they often inhibit protein–protein interactions and thereby may elicit therapeutic effects such as antagonism. Aptamers are discovered using SELEX (systematic evolution of ligands by exponential enrichment), a directed in vitro evolution technique in which large libraries of degenerate oligonucleotides are iteratively and alternately partitioned for target binding. They are then amplified enzymatically until functional sequences are identified by the sequencing of cloned individuals. For most therapeutic purposes, aptamers are truncated to reduce synthesis costs, modified at the sugars and capped at their termini to increase nuclease resistance, and conjugated to polyethylene glycol or another entity to reduce renal filtration rates. The first aptamer approved for a therapeutic application was pegaptanib sodium (Macugen; Pfizer/Eyetech), which was approved in 2004 by the US Food and Drug Administration for macular degeneration. Eight other aptamers are currently undergoing clinical evaluation for various haematology, oncology, ocular and inflammatory indications. Aptamers are ultimately chemically synthesized in a readily scalable process in which specific conjugation points are introduced with defined stereochemistry. Unlike some protein therapeutics, aptamers do not elicit antibodies, and because aptamers generally contain sugars modified at their 2′-positions,…
What is an Aptamer? An aptamer is a short, single-stranded oligonucleotide (DNA or RNA) or peptide that binds to a specific target molecule (e.g., proteins, small molecules, cells, viruses) with high affinity and specificity. Often called "chemical antibodies," they offer advantages like stability, low-cost synthesis, and minimal batch-to-batch variation. The Core Process: SELEX The standard method for aptamer selection is SELEX (Systematic Evolution of Ligands by EXponential enrichment). Basic SELEX Workflow: Library Synthesis: Create a vast random-sequence oligonucleotide library (typically 10¹³ - 10¹⁵ unique sequences) flanked by constant primer regions for PCR amplification. Incubation: The library is incubated with the target molecule under controlled conditions (buffer, temperature, time). Partitioning: Bound sequences are separated from unbound ones. This is the most critical step and varies based on target (e.g., filtration, affinity columns, magnetic bead separation). Elution: Bound aptamers are recovered from the target (e.g., by denaturation or competitive elution). Amplification: The recovered pool is amplified by PCR (for DNA) or RT-PCR (for RNA) to create an enriched library for the next round. Iteration: Steps 2-5 are repeated (typically 8-15 rounds) to progressively enrich for sequences with the highest affinity and specificity. Cloning & Sequencing: The final enriched pool is cloned and sequenced to identify individual aptamer candidates. Key Variants of…
Antibody: A large, Y-shaped protein produced naturally by the immune system (B cells) in response to a foreign substance (antigen). It is a biological molecule. Aptamer: A short, single-stranded piece of DNA or RNA (or modified nucleotides) that is artificially engineered in a lab to bind to a specific target. It is a chemical molecule. Key Differences at a Glance Feature Antibody Aptamer Chemical Nature Protein (IgG, etc.) Nucleic Acid (DNA or RNA) Origin Biological (from animals) Chemical (SELEX process in vitro) Size Large (~150 kDa) Small (~10-30 kDa) Production Requires animal immunization or cell culture. Batch-to-batch variability possible. Synthetic, produced by chemical synthesis. Highly reproducible. Targets Primarily immunogenic targets (proteins, pathogens). Limited to targets that elicit an immune response. Extremely broad: ions, small molecules, proteins, cells, viruses, tissues. Can target toxins or non-immunogenic substances. Stability Sensitive to temperature (often requires refrigeration), pH, and proteases. Can denature. Thermally stable, can be renatured after denaturation. Resistant to harsh conditions (pH, organic solvents). Modification Difficult to modify chemically without affecting function. Site-specific conjugation is complex. Easy to chemically modify with reporters, drugs, or linkers at precise locations. Immunogenicity Can itself trigger an immune response (especially non-human antibodies). Generally low immunogenicity, but can be designed to be non-immunogenic. Cost…
1. Therapeutics & Medicine This is one of the most promising areas. Drugs: The first FDA-approved aptamer drug is Pegaptanib (Macugen) for treating age-related macular degeneration. It binds to VEGF, a protein that promotes abnormal blood vessel growth. Targeted Drug Delivery: Aptamers can be attached to drug nanoparticles or toxins, acting as a "homing device" to deliver the payload specifically to cancer cells or diseased tissues, minimizing side effects. Antidotes: "Antidote" or control oligonucleotides can be designed to bind and deactivate an aptamer's function, allowing for precise control of therapeutic activity—something very difficult with antibodies. Antiviral & Antibacterial Agents: They can bind to and neutralize viruses (like HIV, influenza, SARS-CoV-2) or specific bacterial proteins. 2. Diagnostics & Biosensing Aptamers are powerful tools for detecting molecules. Aptamer-based Assays: Used in ELISA-like formats (sometimes called ELASA) to detect biomarkers for diseases (cancer, infections) in blood or other samples. Point-of-Care Tests: Integrated into portable biosensors (aptasensors) for rapid, on-site detection of pathogens, toxins, or hormones. They can use optical, electrochemical, or mass-sensitive methods. Medical Imaging: Labeled with fluorescent dyes or radioisotopes, aptamers can help visualize tumors or diseased tissues during surgery or in scans. 3. Research & Biotechnology Protein Function Studies: Used to inhibit specific proteins in cells or in vitro to study their biological function, similar to using…
Aptamers are single-stranded DNA or RNA oligonucleotides (typically 20-80 bases) that fold into specific 3D structures capable of binding target molecules with high affinity and specificity, earning them the nickname "chemical antibodies." Their unique properties make them promising agents for targeted liver cancer therapy. Why Aptamers Are Suitable for Liver Cancer Targeting Molecular Recognition Capabilities Can be selected against specific liver cancer biomarkers (ASGPR, GPC3, EGFR, etc.) High binding affinity (nM to pM range) Specific discrimination between cancerous and normal hepatocytes Advantages Over Antibodies Smaller size (5-25 kDa) for better tissue penetration Chemical synthesis without batch variation Lower immunogenicity Easier modification and conjugation Higher thermal stability Key Targeting Strategies for Liver Cancer 1. Targeted Drug Delivery Aptamer-drug conjugates: Direct conjugation of chemotherapeutic agents (doxorubicin, sorafenib derivatives) Nano-carrier guidance: Aptamers decorating nanoparticles, liposomes, or micelles containing drugs Targeted prodrug activation: Aptamer-mediated delivery of enzyme prodrug systems 2. Targeted Gene Therapy Delivery of siRNA/miRNA to regulate oncogene expression CRISPR/Cas9 delivery for gene editing Examples: Anti-GPC3 aptamers delivering VEGF siRNA to inhibit angiogenesis 3. Multifunctional Theranostic Applications Combined imaging (fluorescence, PET, MRI) and therapy Aptamer-conjugated agents for image-guided surgery or ablation 4. Immomodulation Targeting immune checkpoint molecules (PD-1/PD-L1) Redirecting immune cells to tumor sites Clinically Relevant Targets…
